The 100%+ sales growth and expanding physician base suggest accelerating commercial traction for CyPath Lung. Monitor the upcoming Q3 2026 10-Q for actual revenue, gross margin, and cash burn to assess whether this growth is translating into financial sustainability.
Price Chart
Executive Summary
bioAffinity Technologies reported that sales of its CyPath Lung test more than doubled year-over-year through Q3 2026, with over 1,620 tests delivered versus 775 in the prior-year period. The number of ordering physicians increased 89%, and repeat prescribers expanded usage by 48%. This is a positive operational update but lacks hard financial figures such as revenue, gross margin, or cash position.
Key Facts
- Sales of CyPath Lung increased more than 100% through Q3 2026 vs. Q3 2025.
- Over 1,620 tests delivered through Q3 2026 vs. 775 tests through Q3 2025.
- Number of ordering physicians increased 89% in Q3 2026 vs. Q3 2025.
- Physicians who ordered in 2025 increased usage by 48% year-over-year.
- Company highlighted a new distribution agreement with Veteran-Owned AvMEDICAL to expand government healthcare access.
Financial Impact
Sales more than doubled year-over-year through Q3 2026, but no absolute revenue or dollar figures were disclosed.
Risk Factors
- No revenue, margin, or cash position data provided — growth may still be on a small absolute base.
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) and faces evolving FDA/CLIA regulatory requirements.
- Company remains an emerging growth company with ongoing capital needs — no financing update was included.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045867 |
| Exhibit: ex99-1.htm | 0001493152-26-045867 |
| Document: 0001493152-26-045867-index-headers.html | 0001493152-26-045867 |
| Document: 0001493152-26-045867-index.html | 0001493152-26-045867 |
| Document: 0001493152-26-045867.txt | 0001493152-26-045867 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | DEF 14A | $2.83 | awaiting T+60 | — | $2.96 (+4.59%) |
Oct 15, 2026 12d ago | 8-K | $3.96 | awaiting T+60 | — | $2.96 (−25.25%) |
Oct 13, 2026 14d ago | 8-K | $3.63 | awaiting T+60 | — | $2.96 (−18.34%) |
Oct 9, 2026 18d ago | 8-K | $3.90 | awaiting T+60 | — | $2.96 (+24.10%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (+37.35%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (−37.35%) |
Oct 8, 2026 19d ago | 8-K | $5.64 | awaiting T+60 | — | $2.96 (−47.52%) |
Oct 6, 2026 21d ago | 8-K | $6.06 | awaiting T+60 | — | $2.96 (−51.16%) |
Sep 30, 2026 27d ago | 8-K | $6.56 | awaiting T+60 | — | $2.96 (−54.88%) |
Sep 22, 2026 5w ago | 8-K | $8.56 | awaiting T+60 | — | $2.96 (−65.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers